Welcome to our dedicated page for Shattuck Labs news (Ticker: STTK), a resource for investors and traders seeking the latest updates and insights on Shattuck Labs stock.
Shattuck Labs, Inc. (STTK) is a clinical-stage biotechnology company developing innovative dual-function fusion proteins targeting cancer and autoimmune diseases. This page serves as the definitive source for official company announcements, research milestones, and financial updates.
Investors and industry professionals will find timely updates on STTK's clinical trials, regulatory developments, and strategic partnerships. The curated news collection includes press releases on pipeline advancements, collaborations with pharmaceutical leaders, and progress across its proprietary ARC® platform programs.
Key content categories include updates on lead candidates like SL-172154, financial reporting disclosures, and scientific presentations. All materials are sourced directly from company communications to ensure accuracy and compliance.
Bookmark this page for streamlined access to STTK's latest developments in bi-functional therapeutics. Check regularly for critical updates impacting the company's position in immuno-oncology and autoimmune treatment innovation.
Shattuck Labs (NASDAQ: STTK) has announced the closing of a significant private placement of up to $103 million, led by OrbiMed. The funding, assuming full exercise of common stock warrants, is expected to support operations into 2029 and advance SL-325, their novel DR3 blocking antibody, through multiple Phase 2 clinical trials focusing on Inflammatory Bowel Disease (IBD).
The company has also strengthened its Board of Directors with two key appointments: Dr. Daniel Baker, former VP of Immunology at Johnson & Johnson/Janssen, and Dr. Mona Ashiya, Member at OrbiMed. These appointments coincide with the departure of four existing board members, marking Shattuck's strategic repositioning as an immunology and inflammation-focused organization.
Shattuck Labs (NASDAQ: STTK) announced that its Investigational New Drug (IND) application for SL-325, a potentially first-in-class DR3 antagonist antibody for treating Inflammatory Bowel Disease (IBD), is now in effect with the FDA.
The company plans to initiate its Phase 1 clinical trial in Q3 2025, with expected completion in Q2 2026. The trial will be a randomized, double-blind, placebo-controlled study evaluating single and multiple ascending doses in healthy volunteers. The company's financial position is strengthened by cash reserves and anticipated proceeds of up to $103 million from a recent private placement, expected to fund operations into 2029.
Shattuck Labs (NASDAQ: STTK) reported Q2 2025 financial results and business updates. The company submitted an IND application for SL-325, their first-in-class DR3 blocking antibody for IBD treatment, with FDA clearance expected in Q3 2025. The Phase 1 clinical trial is set to begin in Q3 2025.
Financial highlights include cash position of $50.5 million as of June 30, 2025, and an oversubscribed private placement expected to provide up to $103 million in additional funding. Q2 2025 showed improved financials with net loss of $12.5 million ($0.24 per share), compared to $21.6 million ($0.42 per share) in Q2 2024. The combined funding is expected to support operations into 2029.
Shattuck Labs (NASDAQ: STTK) has secured an oversubscribed private placement expected to raise up to $103 million in gross proceeds. The financing includes initial proceeds of $46 million and potential additional proceeds of $57 million from warrant exercises.
The private placement, led by OrbiMed, involves issuing 15.2M shares of common stock and pre-funded warrants for 37.4M shares at $0.8677 per share, with accompanying warrants for 52.6M shares at $1.0846 exercise price. The proceeds will fund the clinical development of SL-325, a first-in-class DR3 blocking antibody for inflammatory bowel disease treatment, through multiple Phase 2 trials.
The financing is contingent upon IND clearance for SL-325, with the combined proceeds expected to fund operations into 2029.
Shattuck Labs (NASDAQ: STTK), a biotechnology company focused on developing novel therapeutics for inflammatory and immune-related diseases, has announced its participation in the upcoming Leerink Partners Therapeutics Forum. The company's CEO, Dr. Taylor Schreiber, will participate in a panel discussion focused on DR3/TL1A and IBD on July 8, 2025.
The presentation, titled "TL1A: Pioneering a New MOA in IBD and Beyond," will take place at 4:15-5:00 PM ET at the Boston Harbor Hotel. Management will also be available for one-on-one meetings during the conference on July 8-9, 2025.
Shattuck Labs (NASDAQ: STTK), a biotechnology company focused on developing novel therapeutics targeting TNF superfamily receptors for inflammatory and immune-related diseases, has announced its participation in the upcoming 24th Annual Needham Virtual Healthcare Conference.
The company's CEO, Taylor Schreiber, M.D., Ph.D., will deliver a presentation on April 9, 2025, at 3:00 PM EDT and participate in one-on-one meetings during the conference, which runs from April 7-10, 2025. A live webcast of the presentation will be accessible through the company's website, with a replay available for up to 30 days afterward.
Shattuck Labs (NASDAQ: STTK) reported its Q4 and full-year 2024 financial results, highlighting the advancement of SL-325, a potential first-in-class DR3 blocking antibody for inflammatory bowel diseases (IBD). The company presented favorable preclinical data at ECCO 2025, demonstrating safety and full receptor occupancy.
Key financial metrics include:
- Cash position of $73.0 million as of December 31, 2024
- Q4 2024 net loss of $18.7 million ($0.37 per share)
- Full-year 2024 net loss of $75.4 million ($1.49 per share)
- R&D expenses decreased to $67.2 million in 2024 from $74.3 million in 2023
The company terminated its SL-172154 program and is now focused on SL-325, with an IND filing expected in Q3 2025. Current cash runway is expected to fund operations into 2027.
Shattuck Labs (NASDAQ: STTK) announced positive preclinical data from an IND-enabling GLP toxicology study of SL-325, their DR3 blocking antibody for inflammatory bowel disease (IBD) treatment. The study, presented at the 20th Congress of ECCO, demonstrated that SL-325 was well-tolerated in non-human primates with no evidence of toxicity or residual agonism.
The study evaluated safety, pharmacokinetics, pharmacodynamics, and immunogenicity over a 4-week dosing period followed by a 4-week recovery period. Three doses (1, 10, and 100 mg/kg) were administered intravenously, showing full and durable DR3 receptor occupancy at all dose levels. No adverse effects, infusion-related reactions, or organ dysfunction were observed, even at the highest dose of 100 mg/kg.
The company expects to file an IND in Q3 2025, with projected human dosing at 1 mg/kg Q2W through Q4W maintenance and 3 mg/kg Q2W through Q8W maintenance.
Shattuck Labs (NASDAQ: STTK) announced an upcoming oral presentation at the 20th Congress of ECCO in Inflammatory Bowel Diseases 2025, taking place in Berlin from February 19-22, 2025. The presentation will showcase results from IND-enabling toxicology studies of SL-325, their first-in-class DR3 blocking antibody, conducted in non-human primates.
Dr. Taylor Schreiber, CEO of Shattuck, will deliver the digital oral presentation titled 'Pre-Clinical Development of SL-325, a High Affinity DR3 Blocking Antibody, for Durable Blockade of the DR3/TL1A Axis in Inflammatory Bowel Disease' on February 20, 2025, at 6:15 PM CET. The presentation materials will be made available on the company's website after the event.
FAQ
What is the current stock price of Shattuck Labs (STTK)?
What is the market cap of Shattuck Labs (STTK)?
